Realtime | Geld | Brief | Zeit |
---|---|---|---|
22,150 | 22,700 | 16.04. |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
MEDICOVER Aktie jetzt für 0€ handeln | |||||
Di | MEDICOVER: Trading update Q1 - Covid-19 third wave drives performance | 3 | Cision News | ||
31.03. | Number of shares and votes in Medicover | 1 | Cision News | ||
24.03. | Notice of annual general meeting of Medicover AB (publ) | 1 | Cision News | ||
12.02. | Medicover: Year-end report January-December 2020 | 366 | PR Newswire | STOCKHOLM, Feb. 12, 2021 /PRNewswire/ --
Fourth quarter
Revenue amounted to €297.7m (€229.7m), an increase of 29.6% with an organic growth of 26.6%. Operating... ► Artikel lesen | |
05.02. | Invitation to media, investor and analyst call for Medicover's Q4 and year-end report 2020 | 2 | Cision News | ||
29.01. | MEDICOVER: Diagnostic Services COO Benedikt von Braunmühl has decided to leave the company | 6 | Cision News | ||
09.12.20 | MEDICOVER: Testing for Covid-19 enables safe travel | 3 | Cision News | ||
30.11.20 | Number of shares and votes in Medicover | 2 | Cision News | ||
06.11.20 | Medicover: Interim report July-September 2020 | 245 | PR Newswire | STOCKHOLM, Nov. 6, 2020 /PRNewswire/ --
Third quarter
Revenue amounted to €262.5m (€212.1m), an increase of 23.8% with an organic growth of 12.3%. Operating profit (EBIT) was €27.3m... ► Artikel lesen | |
29.10.20 | Invitation to media, investor and analyst call for Medicover Q3 report 2020 | - | Cision News | ||
24.07.20 | Medicover: Interim Report April-June 2020 | 348 | PR Newswire | STOCKHOLM, July 24, 2020 /PRNewswire/ -- Second quarter
Revenue amounted to €198.8m (€202.9m), a decrease by 2.1% with an organic reduction of 7.7%. Operating result (EBIT) was €-2.3m... ► Artikel lesen | |
10.06.20 | Medicover Has Completed a Directed Share Issue Raising SEK 1,500 Million | 470 | PR Newswire | NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, CANADA, JAPAN, SOUTH AFRICA OR AUSTRALIA OR ANY OTHER JURISDICTION... ► Artikel lesen | |
10.06.20 | Medicover Intends to Carry Out a Directed Share Issue | 319 | PR Newswire | STOCKHOLM, June 10, 2020 /PRNewswire/ -- Medicover AB (publ) ("Medicover" or the "Company") hereby announces its intention to carry out a directed share issue of Class B shares to Swedish... ► Artikel lesen | |
30.04.20 | Medicover: Interim Report January-March 2020 | 293 | PR Newswire | STOCKHOLM, April 30, 2020 /PRNewswire/ --
Revenue increased by 19.6% to €238.8m (€199.7m). Organic revenue grew by 5.8%. Operating profit (EBIT) was €6.4m (€11.3m), representing an operating... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
TELADOC HEALTH | 159,00 | -1,06 % | NÄCHSTER MEILENSTEIN...: KURS-FEUERWERK KOMMT: Vier neue Arzneimittel-Kandidaten und Vorgespräche zur Zulassung mit US-Behörde FDA! | ||
GERRESHEIMER | 89,05 | +0,74 % | Gerresheimer-Aktie // Es ist genug mit der Konsolidierung | Bei Gerresheimer überzeugten die Zahlen des Q1 nicht. Denn der Umsatz stieg per Ende Februar organisch nur um 3,7 Prozent auf rund 303 Millionen Euro. Dabei sind die Währungseffekte sowie Zu- und Verkäufe... ► Artikel lesen | |
DEXCOM | 332,70 | -0,33 % | Exyte baut die erste Produktionsstätte von Dexcom in Asien | Stuttgart, Deutschland und Penang, Malaysia (ots/PRNewswire) - Exyte, weltweit bekannt für die Planung und den Bau von High-Tech-Anlagen, hat den Zuschlag für ein Fast-Track-Projekt für Dexcom in Penang... ► Artikel lesen | |
INVITAE | 31,150 | -4,56 % | Pharming Group, in collaboration with Invitae Corporation, launches genetic testing program 'navigateAPDS' in US and Canada | - New program expected to improve access to genetic testing for activated PI3K delta syndrome (APDS), an ultra-rare immunodeficiency disease
- Program has potential to advance clinical... ► Artikel lesen | |
EVOFEM BIOSCIENCES | 1,320 | +0,99 % | GSK ViiV's Dovato squares off against Evofem's Phexxi in final FierceMadness DTC ad matchup | ||
ATOSSA THERAPEUTICS | 1,362 | -5,55 % | Atossa Therapeutics Finds Its Share Price Drifting Between Catalysts | ||
EMPOWER CLINICS | 0,467 | +3,78 % | Empower Clinics Inc.: Empower Announces DTC Eligibility | Company Stock Is Now More Accessible to U.S. Investors
VANCOUVER B.C. / ACCESSWIRE / April 15, 2021 / EMPOWER CLINICS INC. (CSE:CBDT)(FRA:8EC)(OTC PINK:EPWCF) ("Empower" or the "Company") an integrated... ► Artikel lesen | |
CYTOSORBENTS | 8,010 | +1,78 % | B. Braun Avitum AG and CytoSorbents Corporation Announce Global Co-Marketing Agreement to Promote the OMNI Continuous Blood Purification Platform with CytoSorb | Joint marketing of CytoSorb with B. Braun's newest OMNI blood purification platform will offer greater access of this advanced treatment of deadly inflammation to critically ill patients.
MELSUNGEN... ► Artikel lesen | |
IMAGIN MEDICAL | 0,482 | +8,31 % | Imagin Medical Closes First Tranche of Convertible Notes Offering | VANCOUVER, BC and BOSTON, MA / ACCESSWIRE / November 10, 2020 / Imagin Medical Inc. (CSE:IME)(OTCQB:IMEXF)(FSE:DPD2) ("Imagin" or the "Company") today announced that further to its press release of... ► Artikel lesen | |
EKSO BIONICS | 4,620 | -3,31 % | EKSO BIONICS HOLDINGS, INC. - 8-K, Current Report | ||
SENSEONICS | 1,600 | -4,02 % | Senseonics Stock Is Speculative, Still a Buy With Good Valuations | ||
STAAR SURGICAL | 99,00 | +2,42 % | Is STAAR Surgical a Buy? | ||
MILLENDO THERAPEUTICS | 0,886 | -0,67 % | Millendo Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
VYANT BIO | 3,070 | +0,56 % | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA - 06.04.2021 | The following instruments on XETRA do have their first trading 06.04.2021 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag am 06.04.2021
Aktien
1 US6612041078 North Mountain Merger... ► Artikel lesen | |
INTERPACE BIOSCIENCES | 6,800 | -0,73 % | Interpace Biosciences, Inc.: Interpace Pharma Solutions Announces New Advanced Offering in RNA Biomarker Analysis |